At a median follow-up of @ months , ibrutinib significantly improved progression-free survival ; the median duration was not reached in the ibrutinib group ( with a rate of progression-free survival of @ % at @ months ) , as compared with a median of @ months in the ofatumumab group ( hazard ratio for progression or death in the ibrutinib group , @ ; P < @ ) .